Disruption of the CRF₂ Receptor Pathway Decreases the Somatic Expression of Opiate Withdrawal

Francesco Papaleo^{1,4}, Sandy Ghozland², Manuela Ingallinesi¹, Amanda J Roberts², George F Koob³ and Angelo Contarino^{*,1}

¹Unité de Nutrition et Neurosciences, Universités Bordeaux 1 et Victor Segalen Bordeaux 2, Talence, France; ²Molecular and Integrative Neurosciences Department, The Scripps Research Institute, La Jolla, CA, USA; ³Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA

Escape from the extremely aversive opiate withdrawal symptoms powerfully motivates compulsive drug-seeking and drug-taking behaviors. The corticotropin-releasing factor (CRF) system is hypothesized to mediate the motivational properties of drug dependence. CRF signaling is transmitted by two receptor pathways, termed CRF₁ and CRF₂. To investigate the role for the CRF₂ receptor pathway in somatic opiate withdrawal, in the present study we used genetically engineered mice deficient in the CRF₂ receptor (CRF₂–/–). We employed a novel, clinically relevant mouse model of ‘spontaneous’ opiate withdrawal as well as a classical opioid receptor antagonist (naloxone)-precipitated opiate withdrawal paradigm. To induce opiate dependence, mice were treated with intermittent escalating morphine doses (20–100 mg/kg, i.p.). We found that 8–128 h after the last opiate injection, CRF₂–/– mice showed decreased levels of major somatic signs of spontaneous opiate withdrawal, such as paw tremor and wet dog shake, as compared to wild-type mice. Similarly, challenge with naloxone 2 h after the last morphine injection induced lower levels of paw tremor and wet dog shake in CRF₂–/– mice as compared to wild-type mice. Despite the differences in somatic signs, wild-type and CRF₂–/– mice displayed similar plasma corticosterone responses to opiate dosing and withdrawal, indicating a marginal role for the hypothalamus–pituitary–adrenal axis in the CRF₂ receptor mediation of opiate withdrawal. Our results unravel a novel role for the CRF₂ receptor pathway in opiate withdrawal. The CRF₂ receptor pathway might be a critical target of therapies aimed at alleviating opiate withdrawal symptoms and reducing relapse to drug intake.

Neuropsychopharmacology (2008) **33**, 2878–2887; doi:10.1038/npp.2008.8; published online 20 February 2008

Keywords: drug dependence; opiate withdrawal; CRF system; CRF₂ receptor; mice

INTRODUCTION

Opiate dependence is a chronic, relapsing disorder with a major impact on public health. Recent reports show an alarming rise in the recreational use of opiate drugs among adolescents, indicating that the incidence rate of opiate dependence may dramatically increase in the next years (NIDA, 2005; OEDT, 2006). In opiate-dependent individuals, heroin ‘highs’ are followed by a severe opiate withdrawal syndrome composed of somatic signs and symptoms, and negative affective states (O’Brien, 1996). Besides a positive reinforcement theory of drug addiction (Shaham *et al*, 2003), studies indicate that avoidance of,

and/or escape from, the extremely aversive opiate withdrawal symptoms powerfully motivates compulsive opiate-seeking and opiate-taking behavior (Carrera *et al*, 1999; Kenny *et al*, 2006; Lu *et al*, 2005; Schulteis and Koob, 1996). The opiate withdrawal syndrome is currently treated mainly by drugs mimicking opiate action, such as methadone (Gonzalez *et al*, 2004; Kreek *et al*, 2002). Opiate-like drugs have greatly ameliorated the management of opiate withdrawal and dependence. However, the abrupt discontinuation of such medications is often followed by relapse into another cycle of opiate abuse and dependence (Kreek *et al*, 2002). The development of novel treatments thus remains a major goal and relies heavily on the understanding of the neural mechanisms underlying the opiate withdrawal syndrome.

The corticotropin-releasing factor (CRF) system is a major coordinator of endocrine and behavioral responses to stress (Heinrichs *et al*, 1994; Rivier and Vale, 1983). The CRF system might also mediate the motivational properties of drug dependence. CRF receptor antagonists reduce stress-induced reinstatement of drug-seeking behavior and ameliorate negative affective-like states associated with alcohol, cocaine, or opiate withdrawal (Erb *et al*, 1998;

*Correspondence: Current address. Dr A Contarino, Unité de Nutrition et Neurosciences, Universités Bordeaux 1 et Victor Segalen Bordeaux 2, Avenue des Facultés—Bâtiment B2, Talence 33405, France, Tel: +33 (0)5 57 57 17 04, Fax: +33 (0)5 40 00 27 76, E-mail: angelo.contarino@nppda.u-bordeaux2.fr

⁴Current address: Clinical Brain Disorders Branch, National Institute of Mental Health, NIH, 10 Center Drive, Bldg 10, Room 4N312, Bethesda, MD 20892-1385, USA.

Received 9 August 2007; revised 19 November 2007; accepted 10 January 2008

Sarnyai *et al*, 1995; Stinus *et al*, 2005; Valdez *et al*, 2002b). The latter studies point to the CRF system as a promising target of novel and effective therapies for drug dependence. In mammals, CRF signaling is mediated by two receptor pathways, termed CRF₁ and CRF₂ (Hauger *et al*, 2003). Genetically engineered mouse models have allowed the discovery of distinct and often opposite functions for the two known CRF receptor pathways (Bale and Vale, 2004; Contarino and Gold, 2002). In particular, CRF₁ receptor-deficient mice display decreased hypothalamus–pituitary–adrenal (HPA) axis as well as behavioral reactions to stressors (Contarino *et al*, 1999; Muller *et al*, 2003; Smith *et al*, 1998; Timpl *et al*, 1998). In net contrast, CRF₂ receptor-deficient mice show increased HPA axis and affective-like responses to stressors (Bale *et al*, 2000; Bale and Vale, 2003; Coste *et al*, 2000, 2006; Kishimoto *et al*, 2000). In line with a major role for the CRF₁ receptor pathway in stress-responsive circuitry, we found that genetic disruption of the CRF₁ receptor pathway eliminated the negative affective-like states of opiate withdrawal (Contarino and Papaleo, 2005). However, in net contrast to affective-like indices, disruption of the CRF₁ receptor pathway exacerbated the somatic expression of opiate withdrawal (Papaleo *et al*, 2007). Thus, our previous studies indicate a complex physiopathological role for the CRF₁ receptor pathway in opiate dependence. However, the role for the CRF₂ receptor pathway in opiate dependence remains largely unexplored.

To examine the specific contribution of the CRF₂ receptor pathway to somatic opiate withdrawal signs, in the present study we used CRF₂ receptor-deficient mice (Bale *et al*, 2000). For this purpose, we employed a clinically relevant mouse model of opiate withdrawal recently developed in our laboratory (Papaleo and Contarino, 2006) as well as a classical opioid receptor antagonist-precipitated opiate withdrawal paradigm (Matthes *et al*, 1996).

MATERIALS AND METHODS

Subjects

Group-housed, littermate female mice on a mixed C57BL/6Jx129 background that were wild-type or CRF₂ receptor-null mutant (CRF₂^{−/−}) were used throughout (Bale *et al*, 2000). Mice were 4–5 months old at the time of the experiments and derived from mating CRF₂^{+/−} mice. Wild-type and CRF₂^{−/−} offspring of CRF₂^{+/−} breeders were identified by PCR analysis of tail DNA. The mice were housed in a colony room maintained at 22 ± 2°C on a 12-h light/dark cycle (lights on from 0800 hours until 2000 hours). Mice used in the naloxone-precipitated opiate withdrawal study were group-housed in a reversed cycle room, with lights on from 2000 hours until 0800 hours, and opiate withdrawal tests were conducted during the dark phase of the 12-h light/dark cycle. Food and water were available *ad libitum*. All studies were conducted in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and the European Communities Council Directive of 24 November 1986 (86/609/EEC), and were approved by the local Animal Care and Use Committee.

Experimental Procedures

The spontaneous opiate withdrawal study was carried out in the Laboratoire Homéostasie–Allostasie–Pathologie (EA 3666), University of Bordeaux, France. During the 5 days preceding the beginning of drug injections, the mice were handled every other day for 1 min for a total of three times. During the following 6 days, wild-type and CRF₂^{−/−} mice were treated every 12 h (0800 and 2000 hours) with increasing doses of morphine according to the following protocol: day 1: 20 mg/kg; day 2: 40 mg/kg; day 3: 60 mg/kg; day 4: 80 mg/kg; day 5: 100 mg/kg; day 6: 100 mg/kg; only one injection in the morning. Then, the mice were tested daily 8, 32, 56, 80, 104, 128, and 152 h after the last morphine injection. For this purpose, mice were individually placed into transparent Plexiglas cylinders (diameter: 23 cm, height: 50 cm) and observed continuously for 30 min for the occurrence of somatic signs of opiate withdrawal. The opioid receptor antagonist-precipitated opiate withdrawal study was carried out at the Molecular & Integrative Neurosciences Department, The Scripps Research Institute (La Jolla, CA, USA). The mice were injected with vehicle or morphine as in the spontaneous opiate withdrawal study, and 2 h after the last injection, they were treated with naloxone (1 mg/kg). The mice were individually placed into transparent plastic cylinders (diameter: 30 cm, height: 60 cm) placed on blotting paper 15 min before the naloxone injection and observed continuously for the occurrence of somatic signs of opiate withdrawal up to 30 min after the naloxone injection.

Jumps, paw tremors, wet dog shakes, body stretches, and sniffing were counted as the number of events occurring during the total test time (graded signs); chewing, teeth chattering, diarrhea, body tremor, piloerection, and palpebral ptosis were instead recorded as the number of 5-min intervals in which it occurred (checked signs, maximal score = 6). Body weights (BW) were recorded each time the mice were injected as well as immediately before and after the 30-min opiate withdrawal tests, and the percentage of BW changes was calculated. To obtain a comprehensive index of the severity of somatic opiate withdrawal including all of the signs examined, for each mouse a global opiate withdrawal score was calculated by summing the raw values of somatic signs (Gellert and Holtzman, 1978).

Evaluation of the HPA Axis Activity during Opiate Treatment and Withdrawal

Another cohort of wild-type and CRF₂^{−/−} mice was treated with increasing doses of morphine (20–100 mg/kg; i.p.), as described above. Just prior to (12-h opiate withdrawal) and 30 and 90 min after the last opiate injection, three tail blood samples were collected from each mouse. Furthermore, 8 h after the last morphine injection, wild-type and CRF₂^{−/−} mice were tested for somatic opiate withdrawal signs, as described above, and blood was collected from the trunk immediately thereafter. Plasma samples were stored at −20°C until corticosterone assay. Plasma corticosterone levels were quantified by radioimmunoassay using a specific corticosterone antibody (ICN Pharmaceuticals). The intra- and interassay coefficients of variation were approximately 3.5 and 8%, respectively.

Drugs

Morphine HCl (20–100 mg/kg, i.p.; Francopia, Gentilly, France) and naloxone HCl (1 mg/kg, s.c.) were dissolved in physiological saline and injected in a volume of 10 ml/kg of BW. Control mice were injected with the same volume of saline.

Statistical Analysis

A two-way analysis of variance (ANOVA) with genotype (wild-type or CRF₂^{-/-}) as a between-subject factor and time as a within-subject repeated measure factor was used to examine percentage of BW loss during the intermittent morphine injections and the 30-min somatic opiate withdrawal tests carried out 8–152 h after the last morphine injection, the percentage of BW recovery following discontinuation of opiate treatment and plasma corticosterone levels being measured just prior to and 30 and 90 min after the last morphine injection. Graded somatic signs of opiate withdrawal were subjected to the Lilliefors test for normality using the Statistica software; data that did not follow a normal distribution were analyzed by the non-parametric Mann–Whitney *U*-test, whereas data that showed normal distributions were examined by parametric tests (eg, ANOVA). Thus, paw tremor, wet dog shake, body stretch, and global opiate withdrawal scores observed during each 30-min test of the spontaneous opiate withdrawal study as well as jump and sniffing of the naloxone-precipitated opiate withdrawal test were analyzed by the Mann–Whitney *U*-test. Paw tremor, wet dog shake, global opiate withdrawal scores, and percentage of BW loss observed during the naloxone-precipitated opiate withdrawal test were analyzed by a two-way ANOVA with genotype (wild-type, CRF₂^{-/-}) and treatment (vehicle, morphine) as independent variables. The Student–Newman–Keuls *post hoc* test was used for individual group comparisons. Checked somatic signs of opiate withdrawal were analyzed by the Mann–Whitney *U*-test. The accepted value for significance was $P < 0.05$. For illustration purposes, data analyzed by non-parametric statistics were represented as median (lower, upper quartiles), whereas data analyzed by parametric statistics were represented as mean $\pm$ SEM.

RESULTS

Disruption of the CRF₂ Receptor Pathway Decreases the Somatic Expression of Spontaneous Opiate Withdrawal

In mice, the abrupt discontinuation of chronic opiate administration is followed by a constellation of somatic signs, such as jumping (escape attempt), paw tremor, wet dog shake, body stretch, diarrhea, chewing, teeth chattering, and palpebral ptosis (Papaleo and Contarino, 2006).

Prior to the beginning of morphine dosing, BWs were 29.6 ± 2.0 or 28.4 ± 0.6 g (mean $\pm$ SEM) for wild-type or CRF₂^{-/-} mice, respectively ($P = \text{NS}$, Student's *t*-test). Twice-daily treatment with increasing morphine doses caused a progressive BW loss. Analysis of percent BW loss revealed no genotype effect ($F_{1,16} = 1.09$, $P = \text{NS}$), a time effect ($F_{5,80} = 114.81$, $P < 0.0001$), but no genotype $\times$ time interaction effect ($F_{5,80} = 0.99$, $P = \text{NS}$). Intermittent

morphine administration produced comparable BW loss in wild-type and CRF₂^{-/-} mice (Supplementary Figure 1a). Also, following morphine discontinuation, wild-type and CRF₂^{-/-} mice displayed similar BW recovery ($F_{1,16} = 0.00$, $P = \text{NS}$; Supplementary Figure 1b).

Starting 8 h after the last morphine injection, the mice were tested every 24 h for the occurrence of somatic opiate withdrawal signs. Analysis of somatic signs of opiate withdrawal revealed that CRF₂^{-/-} mice displayed less paw tremors than wild-type mice 8 h ($U = 2.0$, $P < 0.001$), 32 h ($U = 12.5$, $P < 0.05$), 56 h ($U = 12.0$, $P < 0.05$), 80 h ($U = 12.5$, $P < 0.05$), and 104 h ($U = 15.5$, $P < 0.05$) after the last morphine injection (Figure 1a). Furthermore, CRF₂^{-/-} mice made less wet dog shakes than wild-type mice 32 h ($U = 17.5$, $P < 0.05$), 56 h ($U = 16.0$, $P < 0.05$), 104 h ($U = 9.5$, $P < 0.005$), and 128 h ($U = 18.0$, $P < 0.05$) after the last opiate injection (Figure 1b). Throughout the repeated 30-min tests carried out 8–152 h after the last morphine injection, genetic inactivation of the CRF₂ receptor pathway did not affect the expression of opiate withdrawal-induced body stretch ($U = 27.5$ – 38.5 , $P = \text{NS}$; data not shown), palpebral ptosis ($U = 29.0$ – 38.5 , $P = \text{NS}$; data not shown), chewing ($U = 24.0$ – 39.0 , $P = \text{NS}$; Figure 2a), and diarrhea ($U = 22.0$ – 40.0 , $P = \text{NS}$; Figure 2b). Also, during the repeated tests, wild-type and CRF₂^{-/-} mice displayed similar BW losses ($F_{1,16} = 0.31$, $P = \text{NS}$; data not shown).

Analysis of global opiate withdrawal scores revealed that 8 h ($U = 7.0$, $P < 0.005$), 32 h ($U = 11.0$, $P < 0.01$), 56 h ($U = 9.0$, $P < 0.01$), 80 h ($U = 9.0$, $P < 0.01$), 104 h ($U = 10.0$, $P < 0.01$), and 128 h ($U = 11.0$, $P < 0.01$) after the last morphine injection, CRF₂^{-/-} mice displayed lower levels of global opiate withdrawal than opiate-withdrawn wild-type mice (Figure 3). Genotypes did not differ 152 h after the

Figure 1 Discrete graded somatic signs of spontaneous opiate withdrawal. (a) Paw tremors and (b) wet dog shakes displayed by opiate-withdrawn wild-type or CRF₂^{-/-} mice during repeated daily 30-min tests carried out 8–152 h after the last morphine injection. Values represent the median (lower, upper quartile). $N = 8$ – 10 per genotype. * $P < 0.05$, *** $P < 0.001$ vs opiate-withdrawn wild-type mice at the same time point.

Figure 2 Discrete checked somatic signs of spontaneous opiate withdrawal. (a) Chews and (b) diarrhea displayed by opiate-withdrawn wild-type or CRF₂^{-/-} mice during repeated daily 30-min tests carried out 8–152 h after the last morphine injection. Values represent the median (lower, upper quartile). *N* = 8–10 per genotype.

last opiate administration ($U = 28.0$, $P = \text{NS}$; Figure 3). Thus, at least up to 128 h after the last morphine injection, CRF₂^{-/-} mice displayed reduced levels of spontaneous somatic opiate withdrawal as compared to wild-type mice.

Unaltered Plasma Corticosterone Responses to Opiate Dosing and Withdrawal in CRF₂ Receptor-Deficient Mice

Analysis of plasma corticosterone levels measured just prior to (12-h opiate withdrawal) and 30 and 90 min after the last morphine injection revealed no genotype effect ($F_{1,10} = 0.88$, $P = \text{NS}$), a time effect ($F_{2,20} = 61.28$, $P < 0.0001$), but no genotype $\times$ time interaction effect ($F_{2,20} = 1.18$, $P = \text{NS}$), indicating that CRF₂ receptor deficiency did not affect HPA axis activity related to either opiate dosing or withdrawal (Figure 4a). Notably, plasma corticosterone levels were higher 30 and 90 min after than prior to morphine injection (eg, during opiate withdrawal, $P < 0.0005$; Figure 4a). Plasma corticosterone levels were also measured immediately after a 30-min spontaneous opiate withdrawal test carried out 8 h after the last morphine injection. Similar to the above, opiate-withdrawn CRF₂^{-/-} mice displayed less paw tremors ($U = 3.0$, $P < 0.05$), wet dog shakes ($U = 6.0$, $P = 0.05$), and lower global opiate withdrawal scores ($U = 3.0$, $P < 0.05$) than opiate-withdrawn wild-type mice (data not shown). However, at the end of the behavioral test, opiate-withdrawn CRF₂^{-/-} and wild-type mice showed similar plasma corticosterone levels ($t_{10} = 1.54$, $P = \text{NS}$; Student's *t*-test), ruling out a role for the HPA axis in the CRF₂ receptor-regulated expression of somatic opiate withdrawal (Figure 4b). Notably, plasma corticosterone levels detected immediately after the 30-min somatic opiate withdrawal test

Figure 3 Global score of spontaneous somatic opiate withdrawal. Comprehensive scores (sum of the somatic sign values) displayed by opiate-withdrawn wild-type or CRF₂^{-/-} mice during repeated daily 30-min tests carried out 8–152 h after the last morphine injection. Values represent the median (lower, upper quartile). *N* = 8–10 per genotype. * $P < 0.01$, ** $P < 0.005$ vs opiate-withdrawn wild-type mice at the same time point.

were higher than those observed just prior to the last morphine injection (12-h opiate withdrawal), most likely due to an opiate withdrawal-linked HPA axis response to behavioral testing (for comparisons, see Figure 4a and b).

Disruption of the CRF₂ Receptor Pathway Decreases the Somatic Expression of Naloxone-Precipitated Opiate Withdrawal

Two hours after the last vehicle or morphine injection, wild-type and CRF₂^{-/-} mice were challenged with naloxone (1 mg/kg, s.c.) and immediately tested for the occurrence of somatic signs of opiate withdrawal. Examination of graded signs revealed a genotype $\times$ opiate treatment interaction effect for paw tremor ($F_{1,23} = 4.99$, $P < 0.05$). Opiate-treated wild-type mice made more paw tremors than vehicle-treated wild-type or CRF₂^{-/-} mice ($P < 0.0005$; Figure 5a). In contrast, opiate-treated CRF₂^{-/-} mice did not differ from vehicle-treated wild-type or CRF₂^{-/-} mice. Moreover, opiate-treated CRF₂^{-/-} mice made less paw tremors than opiate-treated wild-type mice ($P < 0.005$; Figure 5a). We also found a genotype $\times$ opiate treatment interaction effect for the wet dog shake sign ($F_{1,23} = 7.68$, $P < 0.05$). Both wild-type and CRF₂^{-/-} mice treated with morphine made more wet dog shakes than vehicle-treated wild-type or CRF₂^{-/-} mice ($P < 0.001$; Figure 5b). However, opiate-treated CRF₂^{-/-} mice made less wet dog shakes than opiate-treated wild-type mice ($P < 0.0005$; Figure 5b). CRF₂ receptor deficiency did not affect the expression of jumping and sniffing. Neither wild-type nor CRF₂^{-/-} mice treated with vehicle and challenged with naloxone displayed jumping or sniffing. In contrast, naloxone produced reliable levels of jumping in opiate-treated wild-type ($U = 0.0$, $P < 0.005$ vs vehicle-treated wild-type mice; Figure 5c) or CRF₂^{-/-} mice ($U = 10.5$, $P < 0.05$ vs vehicle-treated CRF₂^{-/-} mice; Figure 5c). Naloxone also produced reliable levels of sniffing in opiate-treated wild-type ($U = 0.0$, $P < 0.005$ vs vehicle-treated wild-type mice; Figure 5d) or CRF₂^{-/-} mice ($U = 3.5$, $P < 0.005$ vs vehicle-treated CRF₂^{-/-} mice; Figure 5d). Opiate-treated CRF₂^{-/-} mice did not differ from opiate-treated wild-type mice in the expression of jumping ($U = 13.5$, $P = \text{NS}$; Figure 5c) or sniffing ($U = 10.0$, $P = \text{NS}$; Figure 5d).

Figure 4 HPA axis responses to opiate dosing and withdrawal. Plasma corticosterone levels displayed by opiate-withdrawn wild-type or CRF₂^{-/-} mice (a) just prior to (0: 12-h opiate withdrawal) and 30 and 90 min after the last morphine injection and (b) immediately after a 30-min somatic opiate withdrawal test carried out 8 h after the last morphine injection. During 6 consecutive days, wild-type and CRF₂^{-/-} mice were treated every 12 h with increasing morphine doses (20–100 mg/kg; i.p.). Values represent mean $\pm$ SEM. $N = 6$ per genotype.

Figure 5 Discrete graded somatic signs of naloxone-precipitated opiate withdrawal. (a) Paw tremors, (b) wet dog shakes, (c) jumps, and (d) sniffing displayed by vehicle- or morphine-treated wild-type or CRF₂^{-/-} mice during a 30-min test carried out immediately after naloxone (1 mg/kg, s.c.) dosing. Naloxone was administered 2 h after the last vehicle or morphine injection. Values represent mean $\pm$ SEM for paw tremor and wet dog shake, and median (lower, upper quartile) for jump and sniffing. $N = 6$ –8 per group. *** $P < 0.0005$ vs vehicle-treated mice; ** $P < 0.005$, ### $P < 0.0005$ vs morphine-treated wild-type mice; § $P < 0.05$, §§ $P < 0.005$ vs same genotype vehicle-treated mice.

Evaluation of checked somatic signs of naloxone-precipitated opiate withdrawal revealed an opiate treatment effect for chewing, body tremor, palpebral ptosis, and piloerection. Opiate-treated wild-type mice displayed more chews ($U = 0.0$, $P < 0.005$; Figure 6a), body tremors ($U = 0.0$, $P < 0.005$; Figure 6b), palpebral ptoses ($U = 3.0$, $P < 0.01$; Figure 6c), and piloerection ($U = 0.0$, $P < 0.005$; Figure 6d) than vehicle-treated wild-type mice. Similarly, opiate-treated CRF₂^{-/-} mice displayed more chews ($U = 0.0$, $P < 0.001$; Figure 6a), body tremors ($U = 3.5$, $P < 0.005$; Figure 6b), palpebral ptoses ($U = 7.0$, $P < 0.01$; Figure 6c), and piloerection ($U = 7.0$, $P < 0.01$; Figure 6d) than vehicle-treated CRF₂^{-/-} mice. Opiate-treated CRF₂^{-/-} mice did not differ from opiate-treated wild-type mice in the

expression of chewing ($U = 13.5$, $P = \text{NS}$), body tremor ($U = 19.0$, $P = \text{NS}$), palpebral ptosis ($U = 23.5$, $P = \text{NS}$), and piloerection ($U = 20.5$, $P = \text{NS}$). In the naloxone-precipitated opiate withdrawal study, neither the genotype nor the opiate treatment affected the expression of the diarrhea sign. Diarrhea events were as follows: for vehicle-treated mice: wild-type = 0.0 (0.0, 0.0), CRF₂^{-/-} = 0.0 (0.0, 0.0), and for opiate-treated mice: wild-type = 0.0 (0.0, 1.0), CRF₂^{-/-} = 0.0 (0.0, 1.0); median (lower, upper quartile). Also, during the 30-min naloxone-precipitated opiate withdrawal test, the percentage of BW loss was as follows: for vehicle-treated mice: wild-type = 0.95 ± 0.4 , CRF₂^{-/-} = 0.45 ± 0.1 , and for opiate-treated mice: wild-type = 1.08 ± 0.4 , CRF₂^{-/-} = 0.42 ± 0.3 (mean $\pm$ SEM); analysis of

Figure 6 Discrete checked somatic signs of naloxone-precipitated opiate withdrawal. (a) Chews, (b) body tremors, (c) palpebral ptoses, and (d) piloerection displayed by vehicle- or morphine-treated wild-type or CRF₂^{-/-} mice during a 30-min test carried out immediately after naloxone (1 mg/kg, s.c.) dosing. Naloxone was administered 2 h after the last vehicle or morphine injection. Values represent the median (lower, upper quartile). *N* = 6–8 per group. **P* < 0.01, ***P* < 0.005, ****P* < 0.001 vs same genotype vehicle-treated mice.

the latter parameter revealed no genotype effect ($F_{1,23} = 2.67$, $P = \text{NS}$), no opiate treatment effect ($F_{1,23} = 0.06$, $P = \text{NS}$), and no genotype $\times$ opiate treatment interaction effect ($F_{1,23} = 0.04$, $P = \text{NS}$). Thus, similar to the spontaneous opiate withdrawal study described above, CRF₂ receptor deficiency sharply decreased the expression of major somatic signs of opiate withdrawal, such as paw tremor and wet dog shake, also in chronically opiate-treated mice challenged with the opioid receptor antagonist naloxone.

An analysis of global scores revealed a genotype effect ($F_{1,23} = 7.33$, $P < 0.05$), an opiate treatment effect ($F_{1,23} = 28.78$, $P < 0.0001$), and a genotype $\times$ opiate treatment interaction effect ($F_{1,23} = 7.06$, $P < 0.05$). Opiate-treated wild-type mice displayed higher global scores than vehicle-treated wild-type or CRF₂^{-/-} mice ($P < 0.0005$; Figure 7). In net contrast, global scores displayed by opiate-treated CRF₂^{-/-} mice did not differ from those of vehicle-treated wild-type or CRF₂^{-/-} mice ($P = \text{NS}$; Figure 7). Moreover, opiate-treated CRF₂^{-/-} mice displayed lower global opiate withdrawal scores than opiate-treated wild-type mice ($P < 0.0005$; Figure 7). Thus, the lack of functional CRF₂ receptor levels overall decreased the expression of naloxone-precipitated somatic opiate withdrawal signs, reducing global scores of opiate-treated CRF₂^{-/-} mice to drug-naïve mice levels.

DISCUSSION

This report demonstrates, by both a spontaneous opiate withdrawal paradigm recently developed in our laboratory

Figure 7 Global score of naloxone-precipitated somatic opiate withdrawal. Comprehensive scores (sum of the somatic sign values) displayed by vehicle- or morphine-treated wild-type or CRF₂^{-/-} mice during a 30-min test carried out immediately after naloxone (1 mg/kg, s.c.) dosing. Naloxone was administered 2 h after the last vehicle or morphine injection. Values represent mean $\pm$ SEM. *N* = 6–8 per group. ****P* < 0.0005 vs vehicle-treated mice. ###*P* < 0.0005 vs morphine-treated wild-type mice.

(Papaleo and Contarino, 2006) and a classical opioid receptor antagonist-precipitated opiate withdrawal procedure (Matthes *et al*, 1996), a crucial role for the CRF₂ receptor pathway in the somatic expression of opiate withdrawal. In particular, mice lacking functional levels of the CRF₂ receptor pathway displayed decreased somatic reactions to the stressful condition of opiate withdrawal, as compared to wild-type mice.

To mimic the clinical setting, in the present study mice were treated with intermittent escalating morphine doses and opiate withdrawal-related somatic signs assessed following 'spontaneous' clearance of the opiate drug from the body. Using such a clinically oriented experimental

paradigm, we found that CRF₂–/– mice showed lower levels of major somatic signs of opiate withdrawal, such as paw tremor and wet dog shake, than wild-type mice. Genotype differences were observed at several time points, that is, 8–128 h after the last opiate administration, ruling out a genotype-dependent time-shift in the expression of somatic opiate withdrawal. CRF₂ receptor-deficient mice also showed lower global opiate withdrawal scores than wild-type mice, which were evident as soon as 8 h after the last opiate injection, and lasted at least up to 128 h following drug discontinuation. We also investigated the impact of CRF₂ receptor deficiency upon the somatic expression of opioid receptor antagonist (naloxone)-precipitated opiate withdrawal. Prior to naloxone challenge, mice were repeatedly treated with increasing morphine doses as in the spontaneous opiate withdrawal study. We found that CRF₂ receptor deficiency dampened the expression of paw tremor and wet dog shake and decreased global opiate withdrawal scores, a behavioral result very similar to that observed in the spontaneous opiate withdrawal study. Notably, the spontaneous and the opioid receptor antagonist-precipitated opiate withdrawal studies were carried out in two different laboratories (see the Materials and Methods section), strengthening the reliability and significance of our results. Thus, both the spontaneous and the naloxone-precipitated opiate withdrawal studies reported here clearly indicate that genetic disruption of the CRF₂ receptor pathway sharply reduces the severity of major somatic signs of opiate withdrawal, suggesting that activation of the CRF₂ receptor pathway may positively modulate the somatic expression of opiate withdrawal.

The present study also provides novel evidence in favor of major differences between spontaneous and opioid receptor antagonist-precipitated opiate withdrawal in mice. In particular, in either wild-type or CRF₂ receptor-deficient mice, naloxone increased the expression of almost all of the somatic opiate withdrawal signs examined, as compared to the spontaneous opiate withdrawal condition. Moreover, the opioid receptor antagonist triggered somatic signs, such as piloerection, body tremor, sniffing, and jumping, which were not observed during the spontaneous opiate withdrawal study. Accordingly, previous studies showed that challenging opiate-dependent rats with opioid receptor antagonists induced behavioral signs that greatly differed, in both intensity and type, from those observed in animals undergoing spontaneous opiate withdrawal (Cicero *et al*, 2002; Houshyar *et al*, 2004; Linseman, 1977; Mucha *et al*, 1979; Papaleo and Contarino, 2006; Papaleo *et al*, 2007; Ruiz *et al*, 1996).

Genetically engineered mouse models have allowed the identification of distinct and often opposite functions for the two known CRF receptor pathways in HPA axis and affective-like behavioral responses to stress (Bale and Vale, 2004; Contarino and Gold, 2002). In particular, either CRF₁ receptor deficiency or functional antagonism of the CRF₁ receptor pathway decreased anxiety-like and depression-like behavior (Contarino *et al*, 1999; Griebel *et al*, 2002; Hodgson *et al*, 2007; Nielsen *et al*, 2004; Okuyama *et al*, 1999; Smith *et al*, 1998; Timpl *et al*, 1998; Zorrilla *et al*, 2002). Also, CRF₁–/– mice displayed deficient HPA axis responses to stressful events (Contarino and Papaleo, 2005; Papaleo *et al*, 2007; Smith *et al*, 1998; Timpl *et al*, 1998). In

net contrast, genetic disruption of the CRF₂ receptor pathway increased the expression of anxiety-like and depression-like behavior, and exacerbated HPA axis responses to an immobilization stress (Bale *et al*, 2000; Bale and Vale, 2003; Coste *et al*, 2000, 2006; Kishimoto *et al*, 2000). Finally, CRF₁ and CRF₂ receptor pathways were shown to have opposite roles on information processing mechanisms that regulate responses to stressors. In particular, either genetic inactivation or pharmacological antagonism of the CRF₁ receptor pathway increased prepulse inhibition (PPI) of defensive startle responses by sensory stimuli, whereas pharmacological antagonism of the CRF₂ receptor pathway decreased PPI (Risbrough *et al*, 2004). Recently, studies also suggested distinct roles for the CRF₁ (vs the CRF₂) receptor pathway in ethanol dependence. In particular, during acute ethanol withdrawal, CRF₁ receptor activity was shown to mediate excessive ethanol self-administration in dependent animals, whereas activation of the CRF₂ receptor pathway reduced ethanol intake as well as anxiety-like behavior induced by ethanol withdrawal (Funk *et al*, 2007; Valdez *et al*, 2004). We have recently reported that genetic inactivation as well as pharmacological antagonism of the CRF₁ receptor pathway increased and prolonged the somatic expression of opiate withdrawal (Papaleo *et al*, 2007). In contrast to CRF₁ receptor deficiency, in the present study we demonstrate that CRF₂ receptor-deficient mice displayed reduced somatic signs of opiate withdrawal as compared to wild-type mice. Notably, both in our previous and present studies, we used exactly the same experimental paradigm to investigate the role for the CRF₁ or the CRF₂ receptor pathway in opiate withdrawal. Thus, together with our recent study in CRF₁ receptor-null mutant mice (Papaleo *et al*, 2007), the present results provide initial and compelling evidence of opposite roles for the two known CRF receptor pathways in somatic opiate withdrawal. In particular, following abrupt discontinuation of opiate administration, CRF₁ receptor signaling may dampen, whereas the CRF₂ receptor pathway may function to facilitate the somatic expression of opiate withdrawal.

The present findings of decreased somatic opiate withdrawal signs in CRF₂–/– mice are in apparent contrast with studies showing that CRF₂–/– mice displayed increased behavioral responses to stressful events (Bale *et al*, 2000; Bale and Vale, 2003; Coste *et al*, 2006; Kishimoto *et al*, 2000). However, in contrast to CRF₁ receptors, the role for the CRF₂ receptor pathway in stress-responsive circuitry is somewhat less clear. Studies have shown anxiolytic-like effects of CRF₂ receptor activation (Valdez *et al*, 2002a, 2003; Venihaki *et al*, 2004). Moreover, genetic disruption of the CRF₂ receptor pathway resulted in increased anxiety-like and depressive-like behaviors (Bale *et al*, 2000; Bale and Vale, 2003; Coste *et al*, 2006; Kishimoto *et al*, 2000). In contrast, other reports suggested a stress-like activity for the CRF₂ receptor pathway (Henry *et al*, 2006; Ho *et al*, 2001; Radulovic *et al*, 1999; Risbrough *et al*, 2003, 2004). It should be pointed out that the *in vivo* receptor selectivity of the CRF-related peptides and/or peptide doses used in the studies cited above remains uncertain. In the present study, we used a genetic model of CRF₂ receptor inactivation, which might provide a level of molecular specificity that is rarely achieved by pharmacological studies. Prior to being

tested for somatic expression of opiate withdrawal, every 12 h wild-type and CRF₂^{-/-} mice were repeatedly treated with increasing doses of morphine. The twice-daily partial opiate withdrawal that accompanied our drug regimen may have served as a severe chronic stressor. Accordingly, 12 h after morphine dosing, rats treated with a morphine regimen similar to that used in the present study displayed stress-like alterations in the brain, HPA axis, and metabolic functions (Houshyar *et al*, 2004). We also found elevated CRF expression in the paraventricular nucleus of the hypothalamus, a main brain region coordinating HPA axis responses to stress, of opiate-withdrawn wild-type mice treated with the same morphine regimen as that used in the present study (Papaleo *et al*, 2007). Thus, the present results clearly indicate decreased somatic reactions to the stressful event of opiate withdrawal in CRF₂ receptor-deficient mice. However, further studies are needed to better characterize the role for the CRF₂ receptor pathway in drug withdrawal-related stressful conditions.

We recently demonstrated a major role for the HPA axis in behavioral, molecular, and neuroendocrine alterations relevant to the somatic expression of opiate withdrawal (Papaleo *et al*, 2007). In particular, during the stressful condition of opiate withdrawal, CRF₁ receptor-deficient mice showed increased somatic signs as well as profound impairments in the HPA axis and extra-hypothalamic brain stress-responsive circuitry. Interestingly, we found that aberrant behavioral and molecular responses to the stress of opiate withdrawal observed in CRF₁ receptor-deficient mice were largely dependent on the HPA axis impairments associated with the CRF₁ receptor-null mutation. Accordingly, treatment of the CRF₁^{-/-} mice with non-stressful amounts of corticosterone during repeated intermittent dosing with morphine effectively reduced the somatic signs of opiate withdrawal and restored 'wild-type-like' brain responses to the stressful condition of opiate withdrawal (Papaleo *et al*, 2007). Most likely, the 'beneficial' effects of exogenous corticosterone observed in the CRF₁ receptor-deficient mice were due to enduring changes in the HPA system that were taking place throughout the intermittent morphine treatment (Papaleo *et al*, 2007). Thus, 'normalizing' HPA axis activity during intermittent opiate exposure may effectively reduce the severe somatic consequences of opiate withdrawal. In the present study, we provide initial evidence showing that CRF₂^{-/-} mice displayed an intact HPA axis response to drug-related stressful conditions (opiate dosing and opiate withdrawal). In particular, our results clearly show that CRF₂^{-/-} mice were able to mount relatively high plasma corticosterone responses to either opiate dosing (48–114 µg/100 ml) or opiate withdrawal (23–71 µg/100 ml). However, since wild-type and CRF₂^{-/-} mice showed similar plasma corticosterone responses to either opiate dosing or withdrawal, the present findings do not support a role for the HPA axis in the decreased somatic expression of opiate withdrawal displayed by CRF₂ receptor-deficient mice.

The results of the present study bear important implications for research aimed at developing novel medications for the opiate withdrawal syndrome. Human and animal studies indicate that avoidance of, and/or escape from, the extremely stressful condition of opiate withdrawal powerfully motivates compulsive heroin-seeking and

heroin-taking behavior (Baker *et al*, 2004; Carrera *et al*, 1999; Kenny *et al*, 2006; Lu *et al*, 2005; Schulteis and Koob, 1996). Here, we report that genetic disruption of the CRF₂ receptor pathway sharply reduced the expression of major somatic signs of opiate withdrawal. Notably, under both a clinically relevant spontaneous opiate withdrawal and a classical opioid receptor antagonist-precipitated opiate withdrawal paradigm, mice lacking functional levels of the CRF₂ receptor pathway displayed decreased somatic reactions to the stress of opiate withdrawal. These findings unravel a novel role for the CRF₂ receptor pathway in opiate withdrawal and suggest new pharmacological strategies for the management of the opiate withdrawal syndrome.

ACKNOWLEDGEMENTS

We thank Drs Wylie Vale (The Salk Institute, La Jolla, CA, USA) and Antoine Tabarin (Université Victor Segalen Bordeaux 2, Bordeaux, France) for the CRF₂ receptor mutant mouse breeders. FP was supported by a post-doctoral fellowship from the Université Victor Segalen Bordeaux 2, Bordeaux, France. AC was supported by the Université Victor Segalen Bordeaux 2, Bordeaux, France. SG and AJR were supported by NIH Grant AA013523. GFK was supported by NIDA Grant DA04043. We also thank Drs Pierre Costet and Marianne Husson for mouse breeding and genotyping, respectively, and Drs Pierre Kitchener and Piervincenzo Piazza for help with the corticosterone experiment. AC would like to dedicate this paper to Professor D Liguoro.

DISCLOSURE/CONFLICT OF INTEREST

The authors declared that they have no financial conflict of interest.

REFERENCES

- Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC (2004). Addiction motivation reformulated: an affective processing model of negative reinforcement. *Psychol Rev* 111: 33–51.
- Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE *et al* (2000). Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. *Nat Genet* 24: 410–414.
- Bale TL, Vale WW (2003). Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. *J Neurosci* 23: 5295–5301.
- Bale TL, Vale WW (2004). CRF and CRF receptors: role in stress responsivity and other behaviors. *Annu Rev Pharmacol Toxicol* 44: 525–557.
- Carrera MR, Schulteis G, Koob GF (1999). Heroin self-administration in dependent Wistar rats: increased sensitivity to naloxone. *Psychopharmacology (Berl)* 144: 111–120.
- Cicero TJ, Nock B, Meyer ER (2002). Gender-linked differences in the expression of physical dependence in the rat. *Pharmacol Biochem Behav* 72: 691–697.
- Contarino A, Dellu F, Koob GF, Smith GW, Lee KF, Vale W *et al* (1999). Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. *Brain Res* 835: 1–9.

- Contarino A, Gold LH (2002). Targeted mutations of the corticotropin-releasing factor system: effects on physiology and behavior. *Neuropeptides* 36: 103–116.
- Contarino A, Papaleo F (2005). The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. *Proc Natl Acad Sci USA* 102: 18649–18654.
- Coste SC, Heard AD, Phillips TJ, Stenzel-Poore MP (2006). Corticotropin-releasing factor receptor type 2-deficient mice display impaired coping behaviors during stress. *Genes Brain Behav* 5: 131–138.
- Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH et al (2000). Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. *Nat Genet* 24: 403–409.
- Erb S, Shaham Y, Stewart J (1998). The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. *J Neurosci* 18: 5529–5536.
- Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF (2007). Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. *Biol Psychiatry* 61: 78–86.
- Gellert VF, Holtzman SG (1978). Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. *J Pharmacol Exp Ther* 205: 536–546.
- Gonzalez G, Oliveto A, Kosten TR (2004). Combating opiate dependence: a comparison among the available pharmacological options. *Expert Opin Pharmacother* 5: 713–725.
- Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P et al (2002). 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. *J Pharmacol Exp Ther* 301: 333–345.
- Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM (2003). International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. *Pharmacol Rev* 55: 21–26.
- Heinrichs SC, Menzaghi F, Pich EM, Baldwin HA, Rassnick S, Britton KT et al (1994). Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. *Neuropsychopharmacology* 11: 179–186.
- Henry B, Vale W, Markou A (2006). The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. *J Neurosci* 26: 9142–9152.
- Ho SP, Takahashi LK, Livanov V, Spencer K, Leshner T, Maciag C et al (2001). Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. *Brain Res Mol Brain Res* 89: 29–40.
- Hodgson RA, Higgins GA, Guthrie DH, Lu SX, Pond AJ, Mullins DE et al (2007). Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. *Pharmacol Biochem Behav* 86: 431–440.
- Houshyar H, Manalo S, Dallman MF (2004). Time-dependent alterations in mRNA expression of brain neuropeptides regulating energy balance and hypothalamo-pituitary-adrenal activity after withdrawal from intermittent morphine treatment. *J Neurosci* 24: 9414–9424.
- Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF (2006). Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. *J Neurosci* 26: 5894–5900.
- Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F et al (2000). Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. *Nat Genet* 24: 415–419.
- Kreek MJ, LaForge KS, Butelman E (2002). Pharmacotherapy of addictions. *Nat Rev Drug Discov* 1: 710–726.
- Linseman MA (1977). Naloxone-precipitated withdrawal as a function of the morphine-naloxone interval. *Psychopharmacology (Berl)* 54: 159–164.
- Lu L, Chen H, Su W, Ge X, Yue W, Su F et al (2005). Role of withdrawal in reinstatement of morphine-conditioned place preference. *Psychopharmacology (Berl)* 181: 90–100.
- Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I et al (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature* 383: 819–823.
- Mucha RF, Kalant H, Linseman MA (1979). Quantitative relationships among measures of morphine tolerance and physical dependence in the rat. *Pharmacol Biochem Behav* 10: 397–405.
- Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P et al (2003). Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. *Nat Neurosci* 6: 1100–1107.
- NIDA (2005). Monitoring the future: national results on adolescent drug use. Available at <http://www.monitoringthefuture.org>. Accessed May 2007.
- Nielsen DM, Carey GJ, Gold LH (2004). Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. *Eur J Pharmacol* 499: 135–146.
- O'Brien CP (1996). Drug addiction and drug abuse. In: Hardman JG, Limbird LE (eds). *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. McGraw-Hill: New York. pp 557–577.
- OEDT (2006). European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2006. Available at <http://www.emcdda.europa.eu>. Accessed May 2007.
- Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A et al (1999). Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. *J Pharmacol Exp Ther* 289: 926–935.
- Papaleo F, Contarino A (2006). Gender- and morphine dose-linked expression of spontaneous somatic opiate withdrawal in mice. *Behav Brain Res* 170: 110–118.
- Papaleo F, Kitchener P, Contarino A (2007). Disruption of the CRF/CRF(1) receptor stress system exacerbates the somatic signs of opiate withdrawal. *Neuron* 53: 577–589.
- Radulovic J, Ruhmann A, Liepold T, Spiess J (1999). Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. *J Neurosci* 19: 5016–5025.
- Risbrough VB, Hauger RL, Pelleymounter MA, Geyer MA (2003). Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. *Psychopharmacology (Berl)* 170: 178–187.
- Risbrough VB, Hauger RL, Roberts AL, Vale WW, Geyer MA (2004). Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. *J Neurosci* 24: 6545–6552.
- Rivier C, Vale W (1983). Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. *Nature* 305: 325–327.
- Ruiz F, Fournie-Zaluski MC, Roques BP, Maldonado R (1996). Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism. *Br J Pharmacol* 119: 174–182.
- Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G (1995). Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. *Brain Res* 675: 89–97.

- Schulteis G, Koob GF (1996). Reinforcement processes in opiate addiction: a homeostatic model. *Neurochem Res* **21**: 1437–1454.
- Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003). The reinstatement model of drug relapse: history, methodology and major findings. *Psychopharmacology (Berl)* **168**: 3–20.
- Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH et al (1998). Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. *Neuron* **20**: 1093–1102.
- Stinus L, Cador M, Zorrilla EP, Koob GF (2005). Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. *Neuropsychopharmacology* **30**: 90–98.
- Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK et al (1998). Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. *Nat Genet* **19**: 162–166.
- Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, Zorrilla EP (2002a). Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. *Brain Res* **943**: 142–150.
- Valdez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP et al (2002b). Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. *Alcohol Clin Exp Res* **26**: 1494–1501.
- Valdez GR, Sabino V, Koob GF (2004). Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. *Alcohol Clin Exp Res* **28**: 865–872.
- Valdez GR, Zorrilla EP, Rivier J, Vale WW, Koob GF (2003). Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. *Brain Res* **980**: 206–212.
- Venihaki M, Sakihara S, Subramanian S, Dikkes P, Weninger SC, Liapakis G et al (2004). Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. *J Neuroendocrinol* **16**: 411–422.
- Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A (2002). Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. *Brain Res* **952**: 188–199.

Supplementary Information accompanies the paper on the Neuropsychopharmacology website (<http://www.nature.com/npp>)